Pharmacogenomics for Better Treatment of Fungal Infections in Cancer

Launched by THE UNIVERSITY OF QUEENSLAND · Jul 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to improve treatment for patients with blood cancers who develop serious fungal infections. Researchers want to see if a medication called voriconazole can be given in a more personalized way, using genetic testing to determine the best dose for each person. By doing this, the trial aims to help more patients reach the right level of the medication in their system by day 8 of treatment. The study will involve at least 104 children and adults and will also look at how well the new testing and dosing methods can be integrated into regular healthcare practices and whether they are cost-effective.

To be eligible for this trial, participants must be at least 2 years old, have a diagnosed blood cancer, and have a decision made to start voriconazole treatment. They should also be able to attend appointments at the trial site or have follow-up care available. However, patients who are very close to death, have had a specific type of stem cell transplant without prior DNA testing, or have already participated in this trial cannot join. If you participate, you can expect to receive personalized care and be part of an important study that could change how fungal infections are treated in cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 2 years.
• • Written informed consent obtained.
• • Decision to prescribe voriconazole.
• • Diagnosed with haematological malignancy or disorder.
• • Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible
• Exclusion Criteria:
• • Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA
• • Death is likely imminent within 7 days.
• • Previously randomised to this trial